Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.
Saved in:
| Title: | Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. |
|---|---|
| Authors: | Friedman CF; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA friedmac@mskcc.org.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA., Spencer C; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Cabanski CR; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Panageas KS; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Wells DK; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Ribas A; Department of Medicine, University of California Los Angeles, Los Angeles, California, USA., Tawbi H; Department of Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tsai K; Department of Medicine, University of California San Francisco, San Francisco, California, USA., Postow M; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA., Shoushtari A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA., Chapman P; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA., Karakunnel J; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Bucktrout S; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Gherardini P; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Hollmann TJ; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Chen RO; Personalis Inc, Menlo Park, California, USA., Callahan M; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA., LaVallee T; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Ibrahim R; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Wolchok J; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Jan; Vol. 10 (1). |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
